-DOCSTART- -X- O
Management -X- _ O
of -X- _ O
fulminant -X- _ O
hepatic -X- _ O
failure -X- _ O
( -X- _ O
FHF -X- _ O
) -X- _ O
continues -X- _ O
to -X- _ O
be -X- _ O
one -X- _ O
challenging -X- _ O
problem -X- _ O
, -X- _ O
and -X- _ O
experimental -X- _ O
animal -X- _ O
models -X- _ O
resembling -X- _ O
its -X- _ O
clinical -X- _ O
conditions -X- _ O
are -X- _ O
still -X- _ O
needed. -X- _ O
Rabbit -X- _ B-Intervention
hemorrhagic -X- _ I-Intervention
disease -X- _ I-Intervention
( -X- _ I-Intervention
RHD -X- _ I-Intervention
) -X- _ I-Intervention
fullfils -X- _ O
many -X- _ O
requirements -X- _ O
of -X- _ O
an -X- _ O
animal -X- _ O
model -X- _ O
of -X- _ O
FHF. -X- _ O
This -X- _ O
work -X- _ O
investigated -X- _ O
changes -X- _ B-Outcome
in -X- _ I-Outcome
MAPK -X- _ I-Outcome
, -X- _ I-Outcome
NF-κB -X- _ I-Outcome
, -X- _ I-Outcome
AP-1 -X- _ I-Outcome
and -X- _ I-Outcome
STAT -X- _ I-Outcome
pathways -X- _ I-Outcome
during -X- _ I-Outcome
RHD-induced -X- _ I-Outcome
liver -X- _ I-Outcome
injury. -X- _ I-Outcome
Rabbits -X- _ B-Patient
were -X- _ O
infected -X- _ B-Intervention
with -X- _ I-Intervention
2 -X- _ I-Intervention
× -X- _ I-Intervention
10 -X- _ I-Intervention
( -X- _ I-Intervention
4 -X- _ I-Intervention
) -X- _ I-Intervention
hemagglutination -X- _ I-Intervention
units -X- _ I-Intervention
of -X- _ I-Intervention
an -X- _ I-Intervention
RHD -X- _ I-Intervention
virus -X- _ I-Intervention
isolate. -X- _ I-Intervention
Apoptosis -X- _ B-Outcome
was -X- _ I-Outcome
documented -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
caspase-3 -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
substantial -X- _ I-Outcome
PARP -X- _ I-Outcome
proteolysis -X- _ I-Outcome
at -X- _ I-Outcome
36 -X- _ I-Outcome
and -X- _ I-Outcome
48 -X- _ I-Outcome
h -X- _ I-Outcome
postinfection -X- _ I-Outcome
( -X- _ I-Outcome
pi -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Infection -X- _ I-Outcome
induced -X- _ I-Outcome
a -X- _ I-Outcome
marked -X- _ I-Outcome
and -X- _ I-Outcome
maintained -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
TNF-α -X- _ I-Outcome
from -X- _ I-Outcome
12 -X- _ I-Outcome
h -X- _ I-Outcome
pi -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
only -X- _ I-Outcome
a -X- _ I-Outcome
transitory -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
IL-6 -X- _ I-Outcome
expression. -X- _ I-Outcome
Expression -X- _ I-Outcome
of -X- _ I-Outcome
phosphorylated -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
) -X- _ I-Outcome
- -X- _ I-Outcome
JNK -X- _ I-Outcome
, -X- _ I-Outcome
p-p38 -X- _ I-Outcome
and -X- _ I-Outcome
p-ERK1 -X- _ I-Outcome
/ -X- _ I-Outcome
2 -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
elevated -X- _ I-Outcome
at -X- _ I-Outcome
12 -X- _ I-Outcome
h -X- _ I-Outcome
pi. -X- _ I-Outcome
At -X- _ I-Outcome
48 -X- _ I-Outcome
h -X- _ I-Outcome
pi -X- _ I-Outcome
p-JNK -X- _ I-Outcome
expression -X- _ I-Outcome
was -X- _ I-Outcome
maintained -X- _ I-Outcome
at -X- _ I-Outcome
a -X- _ I-Outcome
maximum -X- _ I-Outcome
level -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
p-p38 -X- _ I-Outcome
returned -X- _ I-Outcome
to -X- _ I-Outcome
normality -X- _ I-Outcome
and -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
no -X- _ I-Outcome
p- -X- _ I-Outcome
ERK1 -X- _ I-Outcome
/ -X- _ I-Outcome
2 -X- _ I-Outcome
expression. -X- _ I-Outcome
Activation -X- _ I-Outcome
of -X- _ I-Outcome
NF-κB -X- _ I-Outcome
and -X- _ I-Outcome
AP-1 -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
VCAM-1 -X- _ I-Outcome
and -X- _ I-Outcome
COX-2 -X- _ I-Outcome
were -X- _ I-Outcome
observed. -X- _ I-Outcome
No -X- _ I-Outcome
significant -X- _ I-Outcome
changes -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
STAT1 -X- _ I-Outcome
and -X- _ I-Outcome
STAT3 -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
SOCS3 -X- _ I-Outcome
expression -X- _ I-Outcome
increased -X- _ I-Outcome
significantly. -X- _ I-Outcome
The -X- _ O
current -X- _ O
findings -X- _ O
suggest -X- _ O
that -X- _ O
activation -X- _ B-Outcome
of -X- _ I-Outcome
JNK -X- _ I-Outcome
is -X- _ I-Outcome
an -X- _ I-Outcome
essential -X- _ I-Outcome
component -X- _ I-Outcome
in -X- _ I-Outcome
liver -X- _ I-Outcome
injury -X- _ I-Outcome
mediated -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
RHD -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
lack -X- _ I-Outcome
of -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
STAT3 -X- _ I-Outcome
, -X- _ I-Outcome
probably -X- _ I-Outcome
mediated -X- _ I-Outcome
by -X- _ I-Outcome
SOCS3 -X- _ I-Outcome
over-expression -X- _ I-Outcome
, -X- _ I-Outcome
would -X- _ I-Outcome
contribute -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
regenerative -X- _ I-Outcome
response. -X- _ I-Outcome
Data -X- _ O
show -X- _ O
the -X- _ O
presence -X- _ B-Outcome
of -X- _ I-Outcome
molecular -X- _ I-Outcome
mechanisms -X- _ I-Outcome
contributing -X- _ I-Outcome
to -X- _ I-Outcome
liver -X- _ I-Outcome
damage -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
lack -X- _ I-Outcome
of -X- _ I-Outcome
regeneration -X- _ I-Outcome
and -X- _ O
they -X- _ O
support -X- _ O
the -X- _ O
usefulness -X- _ O
of -X- _ O
this -X- _ O
model -X- _ O
to -X- _ O
investigate -X- _ O
novel -X- _ O
therapeutical -X- _ O
modalities -X- _ O
in -X- _ O
FHF -X- _ O
. -X- _ O

